Mesoblast Limited

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced highly successful preclinical trial results of its adult stem cells in the treatment of degenerative intervertebral disc disease, the leading cause of low back pain.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) is pleased to provide an interview with MD Silviu Itescu on its United States-based associate company Angioblast Systems Inc.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced that its United States-based associate company Angioblast Systems Inc. has closed a A$10 million equity-based financing from institutional and sophisticated investors. New investors oversubscribed the financing, with A$3 million coming from existing Angioblast shareholders.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that institutional and sophisticated investors have made a minimum of A$7 million and up to a maximum of A$10 million equity-based investment in its United States associate company, Angioblast Systems Inc. Settlement formalities are expected to be completed in the next seven days.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (US FDA) for a Phase 2 clinical trial of its allogeneic or "off-the-shelf" adult stem cells in minimally invasive lumbar spinal fusion surgery.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its United States-based associate company Angioblast Systems Inc. has initiated a Phase 2 clinical trial to evaluate the safety and effectiveness of the company's proprietary "off-the-shelf" adult stem cell product Revascor(TM) for improving heart muscle function in patients with the most severe, or class IV, end-stage form of heart failure.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its cash position at 30 June 2009 was A$16.5 million.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) has entered the new financial year with sufficient cash reserves to meet its near-term clinical and commercial objectives. With A$16.5 million cash in hand at the end of June 2009, we can maintain the brisk pace of product development that has been the hallmark of your company since its public listing just 4.5 years ago.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that it had commenced a formal process aimed at obtaining licenses from the Therapeutic Goods Administration (TGA) to commercially manufacture and distribute its adult stem cell products in Australia.

Yesterday the Australian market posted a massive drop following a significant decline in Wall Street. The benchmark S&P/ASX200 index tumbled 3.1 per cent, or 121.3 points, to 3796.9 yesterday, while the broader All Ordinaries lost 117.8 points, or 3.01 per cent, to 3793. Investors would become nervous after the losses in recent trading sessions, although the rebound in commodities prices may help to lift the local market.